A roundup of news from CDMOs/CMOs and suppliers in biomanufacturing, including advanced therapies, with news from Siegfried and Solvias. Highlights below. 

* Siegfried Acquires Dinamiqs to Build a Cell- & Gene-Therapy CDMO  
* Solvias, Vertex in Release-Testing Pact for Gene-Editing Drug  

---

Siegfried Acquires Dinamiqs to build a cell & gene therapy CDMO 
Siegfried has acquired a 95% majority stake in Dinamiqs, a Swiss biotechnology company focused on the development and manufacturing of viral vectors for cell and gene therapies.  

Siegfried intends to bring Dinamiqs’ capabilities to commercial scale and to create a biotech CDMO in that space. This will include the investment in a GMP manufacturing facility, which is on course to go live in 2025.  

Source: Siegfried 

---

Solvias, Vertex in Release-Testing Pact for Gene-Editing Drug 
Solvias, a provider of chemistry, manufacturing, and control (CMC) analytics, and Vertex Pharmaceuticals, a Cambridge, Massachusetts-based bio/pharmaceutical company, have entered a long-term agreement under which Solvias will perform analytical release testing services on a Vertex’s Casgevy (exagamglogene autotemcel or exa-cel), a CRISPR/Cas9 genome-edited cell therapy.  

Casgevy received US Food & Drug Administration (FDA) approval for the treatment of sickle-cell disease in patients 12 years and older with recurrent vaso-occlusive crises. The companies’ collaboration includes establishing testing methods that will be scaled for commercializing Casgevy. Solvias also has invested in preparing one of its global facilities to support the commercial release work. 

Source: Solvias